Výsledky vyhledávání - "Kristyn Y. DiSogra"

Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)

Autor: Aleksander L. Chojecki, Kristyn Y. DiSogra, Justin Arnall, Nicole Cowgill, Amy Soni, Charles H. Packman, Srinivasa Reddy Sanikommu, Nilay A. Shah, Brittany K. Ragon, Thomas G. Knight, Jing Ai, Belinda R. Avalos, Edward A. Copelan, Michael R. Grunwald

Publikováno v: Leukemia & Lymphoma. 63:1515-1517

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc40ab107f6774b022f9671ebced6f5f
https://doi.org/10.1080/10428194.2022.2032037

Zobrazit plný text záznamu

Plný text ve formátu HTML

Characteristics Affecting Durability and Tolerability of Imatinib in Patients Switched from Brand to Generic and Newly Diagnosed Patients Initially Prescribed Generic Imatinib for Chronic Myeloid Leukemia

Autor: Jing Ai, Brittany K. Ragon, Srinivasa R. Sanikommu, Michael R. Grunwald, Edward A. Copelan, Kristyn Y. DiSogra, Thomas G. Knight, Nilay A. Shah, Ariel Denson, Belinda R. Avalos, Aleksander L. Chojecki, Justin Arnall

Publikováno v: Blood. 136:14-17

Introduction Gleevec, Imatinib mesylate, is the first in class BCR-ABL tyrosine kinase inhibitor initially approved to treat CML. In February 2016, generic imatinib products became available. As generic products are not required to offer comparative

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a73af1ff6eba0248f64002bfa3993fc0
https://doi.org/10.1182/blood-2020-137250

Zobrazit plný text záznamu

Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax

Autor: Aleksander L, Chojecki, Justin, Arnall, Danielle, Boselli, Rushil, Patel, Zane, Chiad, Kristyn Y, DiSogra, Allison, Karabinos, Tommy, Chen, Adilen, Cruz, Allison, Verbyla, Jing, Ai, Thomas G, Knight, Brittany K, Ragon, Nilay A, Shah, Srinivasa R, Sanikommu, James, Symanowski, Belinda R, Avalos, Edward A, Copelan, Michael R, Grunwald

Publikováno v: Leukemia Research. 119:106904

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a2efa40498f2dc6f67abe8a31cdbbf
https://doi.org/10.1016/j.leukres.2022.106904

Zobrazit plný text záznamu

Comparative Utilization and Efficacy of Thrombopoietin Receptor Agonists in Relapsed/Refractory Immune Thrombocytopenia

Autor: Justin Arnall, Kristyn Y. DiSogra, Donald C Moore, Lauren Downing, Joseph B. Elmes, Thuy Tran

Publikováno v: American journal of therapeutics. 28(5)

Background The thrombopoietin (TPO) agonists, eltrombopag and romiplostim, stimulate the production of platelets and offer an effective treatment option in relapsed/refractory immune thrombocytopenia (ITP). Recently published 2019 ITP guidelines reco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b5d35c8306a8393716ccc42fbf4bb7f
https://pubmed.ncbi.nlm.nih.gov/33491968

Zobrazit plný text záznamu

Clinical Characteristics and Outcomes of AML Patients Treated with Frontline CPX 351 or HMA/Venetoclax: A Single Institution's Experience

Autor: Brittany K. Ragon, Belinda R. Avalos, Allison Karabinos, Kristyn Y. DiSogra, Jing Ai, Danielle Boselli, Edward A. Copelan, James T. Symanowski, Michael R. Grunwald, Nilay A. Shah, Aleksander L. Chojecki, Justin Arnall, Tommy Chen, Thomas G. Knight, Srinivasa R. Sanikommu

Publikováno v: Blood. 138:1252-1252

Introduction: Treatment options for newly diagnosed patients (pts) with acute myeloid leukemia (AML) have historically been limited. The combination of a hypomethylating agent and venetoclax (HMA/Ven) has emerged as standard of care treatment for eld

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16f358ddf05b869b3431d32f0c63348c
https://doi.org/10.1182/blood-2021-149811

Zobrazit plný text záznamu

Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative

Autor: Brittany K. Ragon, Kristyn Y. DiSogra, Michael R. Grunwald, Nilay A. Shah, Thomas G. Knight, Jing Ai, Justin Arnall, Charles H. Packman, Srinivasa Reddy Sanikommu, Edward A. Copelan, Aleksander L. Chojecki, Nicole Cowgill, Belinda R. Avalos

Publikováno v: Blood. 136:40-41

Background: MF patients (pts) can have significant disease-associated symptoms. Guidelines recommend evaluation of pts' symptom burdens and prognostic risk scores at clinic visits. The myeloproliferative neoplasm symptom assessment form total symptom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7f29feba786c7235268004f8c247d57c
https://doi.org/10.1182/blood-2020-136319

Zobrazit plný text záznamu

Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia

Autor: Justin Arnall, Donald C Moore, Thuy Tran, Kristyn Y. DiSogra, Amanda Janes, Steven I. Park

Publikováno v: Journal of Oncology Pharmacy Practice. :107815522096744

Introduction Ibrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase indicated for the treatment of a variety of B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::553e160129d4805a888b3d3e50488bcc
https://doi.org/10.1177/1078155220967440

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání